Medizinische Universität Graz Austria/Österreich - Forschungsportal - Medical University of Graz

Logo MUG-Forschungsportal

Gewählte Publikation:

SHR Neuro Krebs Kardio Lipid

Heidenreich, S; Ziagkos, D; de Wreede, LC; van Biezen, A; Finke, J; Platzbecker, U; Niederwieser, D; Einsele, H; Bethge, W; Schleuning, M; Beelen, DW; Tischer, J; Nagler, A; Glass, B; Maertens, J; Yáñez, L; Beguin, Y; Sill, H; Scheid, C; Stelljes, M; Ganser, A; Zachée, P; Selleslag, D; de Witte, T; Robin, M; Kröger, N.
Allogeneic Stem Cell Transplantation for Patients Age ≥ 70 Years with Myelodysplastic Syndrome: A Retrospective Study of the MDS Subcommittee of the Chronic Malignancies Working Party of the EBMT.
Biol Blood Marrow Transplant. 2017; 23(1):44-52 [OPEN ACCESS]
Web of Science PubMed FullText FullText_MUG

 

Autor/innen der Med Uni Graz:
Sill Heinz
Altmetrics:

Dimensions Citations:

Plum Analytics:
Abstract:
In this retrospective analysis we evaluated the outcome of 313 patients aged ≥ 70 years in the registry of the European Group for Blood and Marrow Transplantation with myelodysplastic syndrome (MDS; n = 221) and secondary acute myeloid leukemia (n = 92) who underwent allogeneic hematopoietic stem cell transplantation (HSCT) from related (n = 79) or unrelated (n = 234) donors. Median age at HSCT was 72 years (range, 70 to 78). Conditioning regimen was nonmyeloablative (n = 54), reduced intensity (n = 207), or standard intensity (n = 52). Allogeneic HSCT for MDS patients ≥ 70 years was increasingly performed over time. Although during 2000 to 2004 only 16 patients received HSCT, during 2011 to 2013 the number of transplantations increased to 181. The cumulative incidence of nonrelapse mortality at 1 year and relapse at 3 years was 32% and 28%, respectively, with a 3-year overall survival rate of 34%. Good performance, determined by Karnofsky performance status, and recipients' seronegativity for cytomegalovirus was associated with 3-year estimated overall survival rates of 43% (P = .01) and 46% (P = .002), respectively. Conditioning intensity did not impact survival. After careful patient selection, allogeneic HSCT can be offered to patients older than 70 years with MDS. Copyright © 2017 The American Society for Blood and Marrow Transplantation. Published by Elsevier Inc. All rights reserved.
Find related publications in this database (using NLM MeSH Indexing)
Aged -
Cytomegalovirus - immunology
Europe -
Female -
Hematopoietic Stem Cell Transplantation - methods
Hematopoietic Stem Cell Transplantation - mortality
Humans -
Karnofsky Performance Status -
Leukemia, Myeloid, Acute - mortality
Leukemia, Myeloid, Acute - therapy
Male -
Myelodysplastic Syndromes - mortality
Myelodysplastic Syndromes - therapy
Recurrence -
Registries -
Retrospective Studies -
Survival Analysis -
Tissue Donors -
Transplantation Conditioning - methods
Transplantation Conditioning - mortality
Transplantation, Homologous -

Find related publications in this database (Keywords)
Myelodysplastic syndrome
MDS
Acute myeloid leukemia
AML
Karnofsky performance status
CMV
HSCT
EBMT
Age
© Meduni Graz Impressum